STAT

AUGUST 10, 2023

As a new class of obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for nearly half of the patients with insurance claims for GLP-1 prescriptions in 2022.

246

246

PharmaVoice

AUGUST 10, 2023

July’s announcement from the beleaguered drugmaker signals the kind of shift the industry could see more of as M&A and IPOs tick up once again.

130

130

STAT

AUGUST 10, 2023

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome. What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December , Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were

246

246

BioPharma Dive

AUGUST 10, 2023

The deal will help fund a cell-based treatment that completed Phase 1 testing last year and is designed to provide a “functional cure” for patients with HIV infections.

97

97

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

AUGUST 10, 2023

Carol Spence’s vision is flooded with green. As her brush swoops right and swishes left, she’s first transported to a lush spring meadow, then to the canopies of a rainforest — every stroke bringing her to another verdant utopia. Until she hears her daughter scream, “What are you doing?!

246

246

BioPharma Dive

AUGUST 10, 2023

The drug, which will be sold under the brand name Talvey, is now cleared by the FDA to treat multiple myeloma, a blood cancer that J&J has identified as a research priority.

98

98

Board Vitals - Pharmacist

AUGUST 10, 2023

The journey to becoming a certified surgical technologist is a noble one, filled with dedication, perseverance, and a commitment to excellence. At the heart of this journey lies a crucial milestone – the NBSTSA Surgical Technology Exam. This comprehensive exam contains 175 questions (150 graded) with a pass rate of just 73.7% in 2020. How can you best prepare for the CST exam ?

98

98

STAT

AUGUST 10, 2023

As demand for Ozempic and Wegovy surges, a little-noticed warning about the medicines was issued recently by regulators. In late May, the Food and Drug Administration said it received a “few” adverse event reports concerning compounded versions of the injectable medicines, which both contain the same active ingredient, known as semaglutide.

Compounding 234

Compounding Diabetes 234

The Pharmacist

AUGUST 10, 2023

The NHS adult influenza vaccination programme will begin in October this year instead of on its usual September start date, NHS England (NHSE) has confirmed to The Pharmacist. An NHS spokesperson said that this was in order to ‘maximise protection for patients right across the winter months when it is typically colder, and viruses are […] The post Breaking: NSHE confirms October start for flu vaccinations appeared first on The Pharmacist.

Vaccines 95

Vaccines 95

STAT

AUGUST 10, 2023

ST. LOUIS — Firefighter and paramedic Mike Camilleri once had no trouble hauling heavy gear up ladders. Now battling long Covid, he gingerly steps onto a treadmill to learn how his heart handles a simple walk. “This is, like, not a tough-guy test so don’t fake it,” warned Beth Hughes, a physical therapist at Washington University in St.

233

233

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

The Pharmacist

AUGUST 10, 2023

The price concession granted for Atorvastatin 80mg tablets dispensed in July 2023 has increased following a successful appeal from the community pharmacy negotiator. Community Pharmacy England (CPE) has announced the price concession has improved to a rate of £3.91, up from the previously imposed £3.45. And it noted this revised price was ‘high enough to […] The post Price increase for Atorvastatin 80mg dispensed in July appeared first on The Pharmacist.

Community Pharmacies 94

Community Pharmacies 94

STAT

AUGUST 10, 2023

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks , Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss. Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1.

215

215

PharmExec

AUGUST 10, 2023

Hernandez details how the non-profit organization advocates for improved access to care at the community, state, and federal levels, and amplifies education and awareness efforts within its social media communities.

98

98

STAT

AUGUST 10, 2023

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%. But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to the “overwhelming demand for Wegovy.

Drug Development 215

Drug Development 215

Drug Patent Watch

AUGUST 10, 2023

A recent paper published in the journal “Intelligent Medicine” article discusses various aspects of using AI and machine learning in the pharmaceutical industry for drug discovery and development. Results The… The post Artificial Intelligence and Machine Learning in Drug Discovery and Development appeared first on DrugPatentWatch - Make Better Decisions.

98

98

STAT

AUGUST 10, 2023

AdventHealth, a large religious-affiliated hospital system, has sued MultiPlan, alleging the company has worked with health insurers to create a “cartel” that systematically underpays hospitals and doctors for care that is delivered out of an insurance company’s network. AdventHealth claims it has “overwhelming direct evidence” that MultiPlan’s agreements with health insurance companies are anticompetitive, and that MultiPlan’s “multi-year,

Health Insurance Companies 208

Health Insurance Companies Hospitals 208

European Pharmaceutical Review

AUGUST 10, 2023

The US Food and Drug Administration (FDA) has granted accelerated approval of TALVEY (talquetamab-tgvs) to treat multiple myeloma. Janssen Pharmaceutical Companies of Johnson & Johnson’s first-in-class bispecific T-cell engaging antibody showed an overall response rate (ORR) of over 70 percent in heavily pre-treated multiple myeloma. Based on this data, TALVEY is indicated for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, includin

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

STAT

AUGUST 10, 2023

Following an extensive inspection, the Environmental Protection Agency fined Genentech more than $158,000 for hazardous waste violations at a facility in California, the latest instance in which a pharmaceutical company has been cited for failing to adhere to environment regulations. The inspection took place at three locations around a South San Francisco site run by the company, which is a unit of Roche.

Pharmaceutical Companies 203

Pharmaceutical Companies Pharmaceutical Companies 203

PharmExec

AUGUST 10, 2023

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.

Drug Development 98

Drug Development 98

STAT

AUGUST 10, 2023

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences.  Sign up to get this newsletter  delivered in your inbox every Tuesday and Thursday.

Hospitals 188

Hospitals 188

The Honest Apothecary

AUGUST 10, 2023

Have you ever asked yourself this question: “What is the next step in my leadership journey?” It is a good question. Leadership is like climbing a mountain that has no pea or a ladder that has no top rung. Real leaders are generally hungry for the next challenge. They take a tough opportunity, give it their best, then start looking for the next giant to go after.

98

98

STAT

AUGUST 10, 2023

Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his direct-to-consumer venture, Cost Plus Drugs. The company sells generic prescription drugs and boasts more than 2 million members. As a family medicine specialist who has firsthand experience with American households’ dissatisfaction with the state of the nation’s prescription drug marketplace, I believe the enthusiasm for Cost Plus Drugs reveals an appetite for al

Pharmaceutical Companies 181

Pharmaceutical Companies Pharmaceutical Companies 181

Pharma Times

AUGUST 10, 2023

The therapy reaches and activates areas of the brain that are central to cognitive enhancement - News - PharmaTimes

116

116

STAT

AUGUST 10, 2023

Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like a pleasant morning to lift the spirits. A cool breeze and warm sun are enveloping the Pharmalot campus, where the short person has left for another productive day and the official mascots are running about. As for us, we are immersed in the usual daily ritual — quaffing a few cups of stimulation.

Drug Pricing 177

Drug Pricing Diabetes 177

The Pharmacist

AUGUST 10, 2023

The full details of the 2023/24 funding agreement between Community Pharmacy Scotland (CPS) and the Scottish Government have now been released, including guaranteed funding for the sector of almost £300m. The negotiator said that this ‘mutually beneficial deal’ would help support the community pharmacy network after a ‘relentless and punishing 2022/23 in terms of finance, […] The post Scotland funding enough for ‘recuperation’ but not service growth appeared first on The Pharmacist.

Community Pharmacies 80

Community Pharmacies 80

STAT

AUGUST 10, 2023

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine.

171

171

BioPharma Dive

AUGUST 10, 2023

The planned facility in the biotech hotspot of Cambridge will include incubator space for startups and adds to Astellas’ R&D footprint in the Boston area.

98

98

Express Pharma

AUGUST 10, 2023

UPS Healthcare has announced the expansion of its UPS Premier service to India to meet the evolving needs of critical time- and temperature-sensitive healthcare shipments. Indian customers will have access to UPS Premier Gold service benefits, including “first-in, first-off” prioritisation, built-in service recovery features within the UPS global network, and 24/7 control tower monitoring.

Packaging 94

Packaging Labelling 94

BioPharma Dive

AUGUST 10, 2023

The acquisition follows a similar-sized, obesity-focused buyout by Eli Lilly last month and hands Novo a weight-loss medicine already in mid-stage testing.

98

98

Express Pharma

AUGUST 10, 2023

Boehringer Ingelheim announced the launch of NexGard (afoxolaner) S and M in India. This expansion of the NexGard product line for small (weighing 2-4 kg) and medium (weighing 4-10 kg) dogs comes after the introduction of NexGard X and L earlier in 2020. NexGard is indicated for use in dogs and puppies from eight weeks of age and is delivered as a monthly treatment in highly palatable flavored chewables that kill fleas before they can lay eggs, ticks, and mites.

92

92

European Pharmaceutical Review

AUGUST 10, 2023

Amidst numerous warning letters distributed by the US Food and Drug Administration (FDA) to pharmaceutical manufacturers in recent months, in July this year, the US regulatory body published its analysis on drug product quality in 2022. In this paper, the US FDA highlighted that between 2018 and 2022, the quantity of warning letters issued were highest in the US in 2019 (55) and 2022 (47).

Pharmaceutical Manufacturing 86

Pharmaceutical Manufacturing Packaging 86

World Pharma News

AUGUST 10, 2023

Bayer today announced two-year (96 weeks) topline results of the pivotal clinical trial PULSAR in patients with neovascular (wet) age-related macular degeneration (nAMD). The data reinforce sustained vision gains with unprecedented extended treatment intervals of aflibercept 8 mg reaching up to 24 weeks with efficacy and safety comparable to the current standard of care Eylea™ (aflibercept 2 mg) with fixed intervals of 8 weeks.

84

84

Express Pharma

AUGUST 10, 2023

Novo Nordisk has agreed to acquire Inversago Pharma for up to $1.075 billion in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist.

Diabetes 84

Diabetes 84

European Pharmaceutical Review

AUGUST 10, 2023

Novo Nordisk A/S has agreed to acquire Inversago Pharma for up to $1.075 billion. Inversago Pharma is developing CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. What Novo Nordisk will gain from the acquisition Through the acquisition agreement, the pharma company Novo Nordisk intends to investigate Inversago Pharma’s lead development asset, a potential first-in-class small molecule CB1 receptor (CB1r) blocker CB

Diabetes 80

Diabetes 80

Eye on FDA

AUGUST 10, 2023

Every six months, we do a look-back to see what has changed in the way that FDA is communicating. One might not think there is much difference over time, but there is. For example, the air has pretty much gone out of the COVID balloon. And there is more to tell. How many? First of all, consider volume. The number of press releases issued by FDA during the first six months of the year declined to 101 from the 125 issued by June 30 of last year, the lowest number at mid-year since 2017.

Communication 80

Communication Documentation 80